L-arginine supplementation in patients with gestational hypertension

A pilot study

Fabio Facchinetti, George Saade, Isabella Neri, Cristina Pizzi, Monica Longo, Annibale Volpe

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective: To evaluate the effects of L-arginine (L-Arg) supplementation on clinical outcomes and blood pressure (BP) changes in patients with gestational hypertension. Methods: Patients with gestational hypertension and proteinuria (n = 28, >300mg/24 h) and those without proteinuria (n = 46) were randomized in a double-blind design to receive either L-Arg (20g/500 mL intravenously daily, for 5 days followed by 4g/day orally for 2 weeks) or placebo (PL). The primary outcome variable was time from randomization to delivery (Latency). Automated BP readings were obtained every 2 hours, between 8.00 am and 8.00 pm daily, untill the sixth day after treatment. Results: At inclusion, gestational age and proportions of patients with proteinuria did not differ significantly between the PL and L-Arg group. Latency was significantly longer in the L-Arg group compared with the PL group (19.5 ± 16.9 vs. 31.7 ± 25.2 days; p = 0.008). Compared with baseline, both systolic and diastolic BP 6 days after treatment were significantly reduced in the L-Arg group but not in the PL group. The subgroup of patients without proteinuria randomized to the group receiving L-Arg showed a trend to prolong pregnancy, to attenuate the evolution to PE, and to reduce the rate of low birth weight. Conclusions: The treatment with L-Arg seems promising in prolonging pregnancy and reducing blood pressure, particularly in patients with gestational hypertension and without proteinuria. This benefit should be confirmed in larger studies with the power to evaluate the effectiveness of L-Arg in preventing the development to preeclampsia.

Original languageEnglish (US)
Pages (from-to)121-130
Number of pages10
JournalHypertension in Pregnancy
Volume26
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Pregnancy Induced Hypertension
Proteinuria
Arginine
Blood Pressure
Placebos
Pregnancy
Low Birth Weight Infant
Random Allocation
Pre-Eclampsia
Gestational Age
Reading
Therapeutics

Keywords

  • Gestational hypertension
  • L-Arginine supplementation
  • Nitric oxide
  • Preeclampsia

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Internal Medicine

Cite this

L-arginine supplementation in patients with gestational hypertension : A pilot study. / Facchinetti, Fabio; Saade, George; Neri, Isabella; Pizzi, Cristina; Longo, Monica; Volpe, Annibale.

In: Hypertension in Pregnancy, Vol. 26, No. 1, 01.2007, p. 121-130.

Research output: Contribution to journalArticle

Facchinetti, Fabio ; Saade, George ; Neri, Isabella ; Pizzi, Cristina ; Longo, Monica ; Volpe, Annibale. / L-arginine supplementation in patients with gestational hypertension : A pilot study. In: Hypertension in Pregnancy. 2007 ; Vol. 26, No. 1. pp. 121-130.
@article{440c40c0a1bf483f96658393198e54b2,
title = "L-arginine supplementation in patients with gestational hypertension: A pilot study",
abstract = "Objective: To evaluate the effects of L-arginine (L-Arg) supplementation on clinical outcomes and blood pressure (BP) changes in patients with gestational hypertension. Methods: Patients with gestational hypertension and proteinuria (n = 28, >300mg/24 h) and those without proteinuria (n = 46) were randomized in a double-blind design to receive either L-Arg (20g/500 mL intravenously daily, for 5 days followed by 4g/day orally for 2 weeks) or placebo (PL). The primary outcome variable was time from randomization to delivery (Latency). Automated BP readings were obtained every 2 hours, between 8.00 am and 8.00 pm daily, untill the sixth day after treatment. Results: At inclusion, gestational age and proportions of patients with proteinuria did not differ significantly between the PL and L-Arg group. Latency was significantly longer in the L-Arg group compared with the PL group (19.5 ± 16.9 vs. 31.7 ± 25.2 days; p = 0.008). Compared with baseline, both systolic and diastolic BP 6 days after treatment were significantly reduced in the L-Arg group but not in the PL group. The subgroup of patients without proteinuria randomized to the group receiving L-Arg showed a trend to prolong pregnancy, to attenuate the evolution to PE, and to reduce the rate of low birth weight. Conclusions: The treatment with L-Arg seems promising in prolonging pregnancy and reducing blood pressure, particularly in patients with gestational hypertension and without proteinuria. This benefit should be confirmed in larger studies with the power to evaluate the effectiveness of L-Arg in preventing the development to preeclampsia.",
keywords = "Gestational hypertension, L-Arginine supplementation, Nitric oxide, Preeclampsia",
author = "Fabio Facchinetti and George Saade and Isabella Neri and Cristina Pizzi and Monica Longo and Annibale Volpe",
year = "2007",
month = "1",
doi = "10.1080/10641950601147994",
language = "English (US)",
volume = "26",
pages = "121--130",
journal = "Hypertension in Pregnancy",
issn = "1064-1955",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - L-arginine supplementation in patients with gestational hypertension

T2 - A pilot study

AU - Facchinetti, Fabio

AU - Saade, George

AU - Neri, Isabella

AU - Pizzi, Cristina

AU - Longo, Monica

AU - Volpe, Annibale

PY - 2007/1

Y1 - 2007/1

N2 - Objective: To evaluate the effects of L-arginine (L-Arg) supplementation on clinical outcomes and blood pressure (BP) changes in patients with gestational hypertension. Methods: Patients with gestational hypertension and proteinuria (n = 28, >300mg/24 h) and those without proteinuria (n = 46) were randomized in a double-blind design to receive either L-Arg (20g/500 mL intravenously daily, for 5 days followed by 4g/day orally for 2 weeks) or placebo (PL). The primary outcome variable was time from randomization to delivery (Latency). Automated BP readings were obtained every 2 hours, between 8.00 am and 8.00 pm daily, untill the sixth day after treatment. Results: At inclusion, gestational age and proportions of patients with proteinuria did not differ significantly between the PL and L-Arg group. Latency was significantly longer in the L-Arg group compared with the PL group (19.5 ± 16.9 vs. 31.7 ± 25.2 days; p = 0.008). Compared with baseline, both systolic and diastolic BP 6 days after treatment were significantly reduced in the L-Arg group but not in the PL group. The subgroup of patients without proteinuria randomized to the group receiving L-Arg showed a trend to prolong pregnancy, to attenuate the evolution to PE, and to reduce the rate of low birth weight. Conclusions: The treatment with L-Arg seems promising in prolonging pregnancy and reducing blood pressure, particularly in patients with gestational hypertension and without proteinuria. This benefit should be confirmed in larger studies with the power to evaluate the effectiveness of L-Arg in preventing the development to preeclampsia.

AB - Objective: To evaluate the effects of L-arginine (L-Arg) supplementation on clinical outcomes and blood pressure (BP) changes in patients with gestational hypertension. Methods: Patients with gestational hypertension and proteinuria (n = 28, >300mg/24 h) and those without proteinuria (n = 46) were randomized in a double-blind design to receive either L-Arg (20g/500 mL intravenously daily, for 5 days followed by 4g/day orally for 2 weeks) or placebo (PL). The primary outcome variable was time from randomization to delivery (Latency). Automated BP readings were obtained every 2 hours, between 8.00 am and 8.00 pm daily, untill the sixth day after treatment. Results: At inclusion, gestational age and proportions of patients with proteinuria did not differ significantly between the PL and L-Arg group. Latency was significantly longer in the L-Arg group compared with the PL group (19.5 ± 16.9 vs. 31.7 ± 25.2 days; p = 0.008). Compared with baseline, both systolic and diastolic BP 6 days after treatment were significantly reduced in the L-Arg group but not in the PL group. The subgroup of patients without proteinuria randomized to the group receiving L-Arg showed a trend to prolong pregnancy, to attenuate the evolution to PE, and to reduce the rate of low birth weight. Conclusions: The treatment with L-Arg seems promising in prolonging pregnancy and reducing blood pressure, particularly in patients with gestational hypertension and without proteinuria. This benefit should be confirmed in larger studies with the power to evaluate the effectiveness of L-Arg in preventing the development to preeclampsia.

KW - Gestational hypertension

KW - L-Arginine supplementation

KW - Nitric oxide

KW - Preeclampsia

UR - http://www.scopus.com/inward/record.url?scp=34247534142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247534142&partnerID=8YFLogxK

U2 - 10.1080/10641950601147994

DO - 10.1080/10641950601147994

M3 - Article

VL - 26

SP - 121

EP - 130

JO - Hypertension in Pregnancy

JF - Hypertension in Pregnancy

SN - 1064-1955

IS - 1

ER -